Is predicting metastatic phaeochromocytoma and paraganglioma still effective without methoxytyramine?

Competing Interests: CLR holds a research grant from HRA Pharma Rare Disease as Principal Investigator (payment to the University of Birmingham). ESS holds grants from CA20122—Harmonizing Clinical Care and Research on Adrenal Tumours in European Countries (HARMONISATION) and the Turkish Society of Endocrinology and Metabolism. ESS and YSE declare no competing interests.